ATTO — Attovia Therapeutics, Inc.

—
Nasdaq · Health Care · Biotechnology · CIK 2058707 ·
Last close
$14.86
Market Cap
$679.29M
52W High
$28.00
52W Low
$12.94
ADV30
321,060
Next earnings
2026-11-11
Attovia Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops biotherapeutics for immune-mediated diseases in the United States. The company provides ATTOBODY, a biparatopic biologics platform designed to deliver improved treatments. The company's products include ATTO-1310, a novel ATTOBODY-based Fc-fusion protein therapeutic that inhibits IL-31; developed for the treatment of chronic pruritic diseases such as CPUO, high-itch AD, cholestatic pruritus, and CKD-aP; ATTO-2306, an ATTOBODY-based, half-life-extended immunoglobulin G (IgG)-fusion protein therapeutic that inhibits IL-13 and IL-31; developed for the treatment of AD and other immune-mediated skin diseases, such as CSU and PN; and ATTO-1091, a trispecific ATTOBODY-based Fc-fusion protein therapeutic that inhibits TL1A, IL-23, and integrin a4ß7; developed for IBD a chronic immune-mediated condition characterized by persistent inflammation of the gastrointestinal tract, includes ulcerative colitis (UC) and crohn's disease (CD). The company was incorporated in 2022 and is based in San Carlos, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -25,024,000 -22,271,000 411,824,000 115,366,000 14,083,000
Jun 2026 450,000 — -21,803,000 -20,687,000 128,348,000 32,829,000 273,807,000
Mar 2026 0 — -19,955,000 -18,656,000 146,086,000 43,297,000 271,601,000
Dec 2025 990,000 — -18,833,000 -17,258,000 165,893,000 40,193,000 273,329,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-77,946,000
Investing CF
$-162,646,000
Financing CF
$306,193,000
CapEx
$-430,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.51
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-172,624,000
Inventory
—
Receivables
$700,000
ST Investments
$280,573,000
EBIT TTM
$-85,615,000
Pretax Income TTM
$-78,872,000
Interest Exp TTM
—
Analysts
5

Yahoo Snapshot (yfinance, live)

Total Revenue
$1,800,000
EBITDA
$-75,251,000
Free Cash Flow
—
Enterprise Value
$876,014,144
Total Cash
$115,132,000
Total Debt
$4,326,000
Shares Out
45,712,536
Trailing EPS
$-5.53
Book Value
$-24.27
ROE
—
ROA
—
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 2y)

Revenues vs Net Income (last 2y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 1,350,000 -67,159,000 -60,627,000 165,893,000 273,329,000 -107,436,000 -59,199,000
Dec 2024 0 -41,553,000 -39,801,000 76,716,000 123,541,000 -46,825,000 -35,035,000

TTM Snapshot

Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
$128,348,000
Forward EPS
$-2.39

Peers — same industry

TickerNameMarket CapLastDaily %
IAM Iambic Therapeutics, Inc. $674.04M $14.22 —
SLDB Solid Biosciences Inc. $695.33M $6.23 —
DBVT DBV Technologies S.A. $627.78M $9.99 —
AURA Aura Biosciences, Inc. $744.13M $7.15 —
FDMT 4D Molecular Therapeutics, Inc. $608.33M $10.79 —

News headlines (Yahoo Finance, 1h cache)

Attovia Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Corporate Update
2026-11-09 21:05 · Yahoo
Attovia Therapeutics Reports Sustained Itch Relief in Small Study, Plans Phase 2 Trials
2026-11-06 11:14 · Yahoo
Attovia Therapeutics Announces Positive Topline 12-Week Results from Phase 1b Study of ATTO-1310 in Patients with Chronic Pruritus and High-Itch Atopic Dermatitis
2026-11-05 21:05 · Yahoo
Attovia Therapeutics to Participate in Upcoming Investor Conferences
2026-10-27 20:05 · Yahoo
Attovia Therapeutics to Present New Data on ATTO-1310 and ATTO-2306 at EADV 2026 and Fall Clinical Dermatology Conference 2026
2026-09-28 20:05 · Yahoo
Attovia Therapeutics (ATTO) Pulls Back As Investors Ask If The Valuation Still Fits
2026-09-22 03:25 · Yahoo
Attovia Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update
2026-09-02 20:05 · Yahoo
Attovia Therapeutics Could Serve as Key Player in Immunology, Inflammation, RBC Says
2026-08-31 15:16 · Yahoo
Was Moderna Stock's Cancer Vaccine Run Visible In Advance?
2026-09-22 17:39 · Yahoo
Deere upgraded, Lumentum initiated: Wall Street's top analyst calls
2026-08-31 13:45 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.